PDS Biotechnology (PDSB) Current Assets (2014 - 2026)
PDS Biotechnology's (PDSB) quarterly Current Assets came in at $28.3 million in Q4 2025, down 37.29% YoY from $45.1 million in Q4 2024, and up 1.29% on a QoQ basis from $27.9 million in Q3 2025.
PDS Biotechnology (PDSB) Current Assets (2014 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Current Assets data on file, last reported at $28.3 million in Q4 2025.
- Quarterly Current Assets fell 37.29% year-over-year to $28.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $28.3 million (down 37.29% YoY) and the FY2025 annual result came in at $28.3 million, down 37.29% from the prior year.
- Current Assets climbed to $28.3 million in Q4 2025, from $27.9 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $76.9 million in Q2 2021 to a low of $27.3 million in Q1 2021.
- A 5-year average of $55.8 million and a median of $59.6 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2021 — Current Assets jumped 295.73% — and 2025, when it plunged 46.49%.
- Tracing PDSB's Current Assets over 5 years: stood at $66.8 million in 2021, then climbed by 14.42% to $76.5 million in 2022, then declined by 22.78% to $59.1 million in 2023, then fell by 23.71% to $45.1 million in 2024, then slumped by 37.29% to $28.3 million in 2025.
- The last three Current Assets figures came in at $28.3 million (Q4 2025), $27.9 million (Q3 2025), and $33.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 1.76 Bn |
| 10 | PDS Biotechnology | 12.06 Mn | 12.06 Mn | - | 7.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.05 Mn |
| Dec 31, 2025 | 28.25 Mn |
| Sep 30, 2025 | 27.89 Mn |
| Jun 30, 2025 | 33.65 Mn |
| Mar 31, 2025 | 42.47 Mn |
| Dec 31, 2024 | 45.05 Mn |
| Sep 30, 2024 | 52.13 Mn |
| Jun 30, 2024 | 60.16 Mn |
| Mar 31, 2024 | 68.69 Mn |
| Dec 31, 2023 | 59.06 Mn |
| Sep 30, 2023 | 56.84 Mn |
| Jun 30, 2023 | 63.35 Mn |
| Mar 31, 2023 | 67.97 Mn |
| Dec 31, 2022 | 76.48 Mn |
| Sep 30, 2022 | 74.41 Mn |
| Jun 30, 2022 | 55.74 Mn |
| Mar 31, 2022 | 60.73 Mn |
| Dec 31, 2021 | 66.84 Mn |
| Sep 30, 2021 | 71.34 Mn |
| Jun 30, 2021 | 76.93 Mn |